#LEGALIZEDRUGS
No adverse cognitive effects of ketamine or esketamine for treatment-resistant depression
Peer-Reviewed PublicationAugust 12, 2021 – Used for the treatment of depression that does not respond to standard antidepressant medications, the anesthesia drug ketamine – and the related drug esketamine, recently approved for depression treatment – has no important adverse effects on memory, attention, or other cognitive processes, concludes a systematic review of medical research in the September/October issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
"Current evidence suggests that ketamine and esketamine do not appear to exert significant deleterious neurocognitive effects in treatment-resistant depression," according to the new research, led by Breno Souza-Marques, BA, and Lucas C. Quarantini, MD, PhD, of Federal University of Bahia, Salvador, Brazil. In fact, some cognitive functions improved 7 to 13 days after repeated ketamine infusions.
Evidence supports cognitive safety of ketamine and esketamine for depression treatment
Ketamine is a widely used surgical anesthetic that produces a detached, dreamlike state. Multiple studies have shown that at low doses, ketamine can have rapid antidepressant effects – typically improving mood within 24 hours to 7 days. Similar benefits have been reported with esketamine, a version of the drug recently approved for use in patients with treatment-resistant depression. Although ketamine is not yet approved for treatment of depression, some physicians prescribe it for that purpose on an "off-label" basis.
However, there are potential safety concerns with ketamine, which is "a highly sought-after recreational drug," according to the authors. Studies have reported memory impairment after long-term recreational use of ketamine, as well as in medical studies in which healthy volunteers received just one infusion. That's particularly worrisome because memory problems and other cognitive symptoms – such as difficulties with thinking and concentrating – are a key aspect of major depressive disorder. Cognitive symptoms may continue even after mood improves.
To investigate the cognitive safety of ketamine and esketamine, Mr. Souza-Marques, Dr. Quarantini, and colleagues searched the medical literature for studies in which one of these drugs was given to patients who had treatment-resistant depression. Definitions vary, but most experts consider depression "treatment-resistant" if it persists after the patient has tried at least two different antidepressants.
The team identified 14 studies that collectively involved 1,019 patients: one study of esketamine nasal spray for 44 weeks, seven studies of a single ketamine intravenous infusion, and six studies in which patients received six ketamine infusions over two or three weeks. Neuropsychological performance assessment was variable for the ketamine studies (1 study at 40 minutes, 1 study at 24 hours, 1 study at 3 days, and 1 study at 7 days), while the esketamine study performed repeated assessments at 28 days, 20 weeks, 32 weeks, and 44 weeks.
The esketamine study showed no changes in cognitive performance. Five studies of ketamine actually reported improvements in memory, processing speed (the time it takes to complete a mental task), or cognitive flexibility (the ability to switch between mental tasks or thoughts).
Only one of the 14 studies reported cognitive impairment after ketamine treatment. Memory was worse 24 hours after six ketamine infusions, and processing speed was worse 24 hours after a single infusion, but these deficits were no longer present seven days after treatment. Moreover, the group that received multiple infusions showed improved processing speed, cognitive flexibility, and memory. Despite this encouraging evidence, further studies are needed to assess the longer-term neurocognitive effects of these drugs.
Some studies showed that individuals who had certain cognitive attributes before treatment—poorer attention, slower processing speed, or better memory—were more likely to respond to ketamine. The researchers conclude: "Results suggest possible neuropsychological profiles predictive of antidepressant response to ketamine, such as lower attention, slower processing speed, or higher working memory, that should be further assessed in future studies, as these results could provide time-saving evidence to clinicians and mental health practitioners."
DOI: 10.1097/HRP.0000000000000312
###
About the Harvard Review of Psychiatry
The Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer reviewed and not industry sponsored. It is the property of Harvard University and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals. Articles encompass major issues in contemporary psychiatry, including neuroscience, epidemiology, psychopharmacology, psychotherapy, history of psychiatry, and ethics.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
JOURNAL
Harvard Review of Psychiatry
No comments:
Post a Comment